Eli Lilly Raises Revenue Outlook Amid High Drug Demand

Eli Lilly reported financial results that exceeded expectations in the third quarter. The performance was supported by the rapid sales growth of Zepbound and Mounjaro.

The pharmaceutical company raised its annual revenue forecast. The estimate for 2026 now ranges between 91 billion and 92 billion dollars. The previous target had a ceiling of 87 billion dollars.

CEO Dave Ricks highlighted the expansion potential of the obesity market. The company is seeing increased adoption following the inclusion of weight-loss treatments by Medicare in the United States.

Global sales of Mounjaro rose 65 percent during the period. The international market saw a 93 percent jump in revenue for this specific drug. Zepbound also contributed to the company's robust business volume.

Adjusted earnings per share are expected to be between 35 and 36 dollars this year. The company is using part of its gains to fund strategic acquisitions in areas such as autoimmune diseases. The pharmaceutical sector remains a key pillar of liquidity in the US stock market.

Capital flow into large pharmaceutical companies may reduce the search for higher-risk assets. This tends to strengthen the dollar against emerging market currencies and pressure the appetite for volatile assets like Bitcoin.